The Diagnosis and Management of Reversible Dementia Syndromes
Purpose of Review This article discusses the diagnostic evaluation and management of reversible dementia syndromes. It highlights clinical syndromes and explores the recent literature implicating certain reversible factors in Alzheimer’s disease pathogenesis. Recent Findings The prevalence of fully reversible dementia is low, but there is growing awareness for potentially reversible contributors to neurodegenerative disease. In particular, exposure to anticholinergic medications, obstructive sleep apnea, and depression have emerged as potentially modifiable targets in the pathogenesis of preclinical and early Alzheimer’s disease. Treatment of these factors may not only reverse any direct cognitive effects but also prevent downstream neurodegeneration. Summary There is substantial opportunity to improve outcome in patients with dementia due to reversible etiologies. Even in the setting of primary neurodegenerative disease, conscientious effort is required to recognize and address reversible contributors..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current treatment options in neurology - 23(2021), 1 vom: Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bevins, Elizabeth A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| doi: |
10.1007/s11940-020-00657-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR042569303 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR042569303 | ||
| 003 | DE-627 | ||
| 005 | 20230519191508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210106s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11940-020-00657-x |2 doi | |
| 035 | |a (DE-627)SPR042569303 | ||
| 035 | |a (DE-599)SPRs11940-020-00657-x-e | ||
| 035 | |a (SPR)s11940-020-00657-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Bevins, Elizabeth A. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Diagnosis and Management of Reversible Dementia Syndromes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose of Review This article discusses the diagnostic evaluation and management of reversible dementia syndromes. It highlights clinical syndromes and explores the recent literature implicating certain reversible factors in Alzheimer’s disease pathogenesis. Recent Findings The prevalence of fully reversible dementia is low, but there is growing awareness for potentially reversible contributors to neurodegenerative disease. In particular, exposure to anticholinergic medications, obstructive sleep apnea, and depression have emerged as potentially modifiable targets in the pathogenesis of preclinical and early Alzheimer’s disease. Treatment of these factors may not only reverse any direct cognitive effects but also prevent downstream neurodegeneration. Summary There is substantial opportunity to improve outcome in patients with dementia due to reversible etiologies. Even in the setting of primary neurodegenerative disease, conscientious effort is required to recognize and address reversible contributors. | ||
| 650 | 4 | |a Neurodegeneration |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dementia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Reversible |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Risk factors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nutritional |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anticholinergic medications |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Obstructive sleep apnea |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Depression |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Normal pressure hydrocephalus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Autoimmune |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hashimoto |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurosyphilis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Whipples |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Transient epileptic amnesia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vitamin B12 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Peters, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Léger, Gabriel C. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current treatment options in neurology |d Philadelphia, Pa. : Current Science Inc., 1999 |g 23(2021), 1 vom: Jan. |w (DE-627)SPR023068833 |w (DE-600)2076603-8 |x 1534-3138 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:1 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11940-020-00657-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.90 |q ASE |
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 1 |c 01 | ||